CAREDX INC (CDNA) Stock Price, Quote, News and Overview
NASDAQ:CDNA - Nasdaq - US14167L1035 - Common Stock - Currency: USD
CDNA Quote, Performance and Key Statistics
19.04
+0.01 (+0.05%)
The current stock price of CDNA is 19.04 USD. In the past month the price increased by 11.67%. In the past year, price increased by 35.42%.
CDNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.04 | 327.31B | ||
| AMGN | AMGEN INC | 13.94 | 155.58B | ||
| GILD | GILEAD SCIENCES INC | 14.02 | 134.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.5 | 55.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.38B | ||
| ARGX | ARGENX SE - ADR | 94.29 | 33.10B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.32 | 26.73B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.61B | ||
| NTRA | NATERA INC | N/A | 23.47B | ||
| INSM | INSMED INC | N/A | 18.70B | ||
| BIIB | BIOGEN INC | 8.03 | 18.62B |
Related stock screener links
About CDNA
Company Profile
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in Brisbane California, California and currently employs 644 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. The company offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. The company also offers a diverse portfolio of digital solutions to transplant centers.
Company Info
CAREDX INC
8000 Marina Blvd, 4th Floor
Brisbane California CALIFORNIA 94080 US
CEO: Reginald Seeto
Employees: 647
Phone: 14152872300
CAREDX INC / CDNA FAQ
What is the stock price of CAREDX INC today?
The current stock price of CDNA is 19.04 USD. The price increased by 0.05% in the last trading session.
What is the ticker symbol for CAREDX INC stock?
The exchange symbol of CAREDX INC is CDNA and it is listed on the Nasdaq exchange.
On which exchange is CDNA stock listed?
CDNA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CAREDX INC stock?
15 analysts have analysed CDNA and the average price target is 29.58 USD. This implies a price increase of 55.36% is expected in the next year compared to the current price of 19.04. Check the CAREDX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CAREDX INC worth?
CAREDX INC (CDNA) has a market capitalization of 1.06B USD. This makes CDNA a Small Cap stock.
How many employees does CAREDX INC have?
CAREDX INC (CDNA) currently has 647 employees.
What are the support and resistance levels for CAREDX INC (CDNA) stock?
CAREDX INC (CDNA) has a support level at 18.79 and a resistance level at 19.32. Check the full technical report for a detailed analysis of CDNA support and resistance levels.
Is CAREDX INC (CDNA) expected to grow?
The Revenue of CAREDX INC (CDNA) is expected to grow by 11.91% in the next year. Check the estimates tab for more information on the CDNA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CAREDX INC (CDNA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CDNA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CDNA, evaluating the profitability, health, valuation and growth aspects
- CAREDX INC (CDNA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CAREDX INC (CDNA) Sales and EPS estimates to see what analysts future expectations are.
- CAREDX INC (CDNA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CAREDX INC (CDNA) Insider and Institutional Ownership to learn about the owners and their transactions.
- CAREDX INC (CDNA) Stock Chart to make your own analysis
- CAREDX INC (CDNA) Latest news and press-releases to stay up to date.
Does CAREDX INC (CDNA) stock pay dividends?
CDNA does not pay a dividend.
When does CAREDX INC (CDNA) report earnings?
CAREDX INC (CDNA) will report earnings on 2025-07-29, after the market close.
What is the Price/Earnings (PE) ratio of CAREDX INC (CDNA)?
The PE ratio for CAREDX INC (CDNA) is 28.85. This is based on the reported non-GAAP earnings per share of 0.66 and the current share price of 19.04 USD. Check the full fundamental report for a full analysis of the valuation metrics for CDNA.
What is the Short Interest ratio of CAREDX INC (CDNA) stock?
The outstanding short interest for CAREDX INC (CDNA) is 12.06% of its float. Check the ownership tab for more information on the CDNA short interest.
CDNA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CDNA. When comparing the yearly performance of all stocks, CDNA is one of the better performing stocks in the market, outperforming 83.67% of all stocks.
CDNA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to CDNA. CDNA has an excellent financial health rating, but there are some minor concerns on its profitability.
CDNA Financial Highlights
Over the last trailing twelve months CDNA reported a non-GAAP Earnings per Share(EPS) of 0.66. The EPS increased by 217.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.99% | ||
| ROA | 12.02% | ||
| ROE | 15.51% | ||
| Debt/Equity | 0 |
CDNA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to CDNA. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 13.3% and a revenue growth 11.91% for CDNA